Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

Completed

• Conditions: COVID-19

• Registration Number: NCT04380779
• Lead Sponsor: Manuel Monreal

Brief Summary

The main objectives are:

* To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses.

* To identify variables associated to higher risk of bleeding.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-13
• Study First Submitted: 2020-05-07
• Study First Submitted QC: 2020-05-07
• Study First Posted: 2020-05-08
• Primary Completion: 2020-10-13
• Study Completion: 2020-10-13
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-11
• Last Update Posted: 2020-12-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2430

Inclusion Criteria

• Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis doses.
• Admission to hospital.

Exclusion Criteria

• Patients treated with ECMO (Extracorporeal membrane oxygenation).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding events and complications	30 days	Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.

Trial Locations

Locations (1)

Manuel Monreal; 🇪🇸 Badalona, Barcelona, Spain